139 related articles for article (PubMed ID: 15557554)
1. Activating Met mutations produce unique tumor profiles in mice with selective duplication of the mutant allele.
Graveel C; Su Y; Koeman J; Wang LM; Tessarollo L; Fiscella M; Birchmeier C; Swiatek P; Bronson R; Vande Woude G
Proc Natl Acad Sci U S A; 2004 Dec; 101(49):17198-203. PubMed ID: 15557554
[TBL] [Abstract][Full Text] [Related]
2. A mouse model of activating Met mutations.
Graveel CR; London CA; Vande Woude GF
Cell Cycle; 2005 Apr; 4(4):518-20. PubMed ID: 15738649
[TBL] [Abstract][Full Text] [Related]
3. Novel mutations of the MET proto-oncogene in papillary renal carcinomas.
Schmidt L; Junker K; Nakaigawa N; Kinjerski T; Weirich G; Miller M; Lubensky I; Neumann HP; Brauch H; Decker J; Vocke C; Brown JA; Jenkins R; Richard S; Bergerheim U; Gerrard B; Dean M; Linehan WM; Zbar B
Oncogene; 1999 Apr; 18(14):2343-50. PubMed ID: 10327054
[TBL] [Abstract][Full Text] [Related]
4. A novel germ line juxtamembrane Met mutation in human gastric cancer.
Lee JH; Han SU; Cho H; Jennings B; Gerrard B; Dean M; Schmidt L; Zbar B; Vande Woude GF
Oncogene; 2000 Oct; 19(43):4947-53. PubMed ID: 11042681
[TBL] [Abstract][Full Text] [Related]
5. Duplication and overexpression of the mutant allele of the MET proto-oncogene in multiple hereditary papillary renal cell tumours.
Fischer J; Palmedo G; von Knobloch R; Bugert P; Prayer-Galetti T; Pagano F; Kovacs G
Oncogene; 1998 Aug; 17(6):733-9. PubMed ID: 9715275
[TBL] [Abstract][Full Text] [Related]
6. Trisomy 7-harbouring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas.
Zhuang Z; Park WS; Pack S; Schmidt L; Vortmeyer AO; Pak E; Pham T; Weil RJ; Candidus S; Lubensky IA; Linehan WM; Zbar B; Weirich G
Nat Genet; 1998 Sep; 20(1):66-9. PubMed ID: 9731534
[TBL] [Abstract][Full Text] [Related]
7. Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion.
Lorenzato A; Olivero M; Patanè S; Rosso E; Oliaro A; Comoglio PM; Di Renzo MF
Cancer Res; 2002 Dec; 62(23):7025-30. PubMed ID: 12460923
[TBL] [Abstract][Full Text] [Related]
8. Missense mutation of the MET gene detected in human glioma.
Moon YW; Weil RJ; Pack SD; Park WS; Pak E; Pham T; Karkera JD; Kim HK; Vortmeyer AO; Fuller BG; Zhuang Z
Mod Pathol; 2000 Sep; 13(9):973-7. PubMed ID: 11007037
[TBL] [Abstract][Full Text] [Related]
9. Germline and somatic c-met mutations in multifocal/bilateral and sporadic papillary renal carcinomas of selected patients.
Salvi A; Marchina E; Benetti A; Grigolato P; De Petro G; Barlati S
Int J Oncol; 2008 Aug; 33(2):271-6. PubMed ID: 18636147
[TBL] [Abstract][Full Text] [Related]
10. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention.
Christensen JG; Burrows J; Salgia R
Cancer Lett; 2005 Jul; 225(1):1-26. PubMed ID: 15922853
[TBL] [Abstract][Full Text] [Related]
11. Identification of a novel germline MET mutation in dogs.
Liao AT; McMahon M; London CA
Anim Genet; 2006 Jun; 37(3):248-52. PubMed ID: 16734685
[TBL] [Abstract][Full Text] [Related]
12. Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas.
Di Renzo MF; Olivero M; Martone T; Maffe A; Maggiora P; Stefani AD; Valente G; Giordano S; Cortesina G; Comoglio PM
Oncogene; 2000 Mar; 19(12):1547-55. PubMed ID: 10734314
[TBL] [Abstract][Full Text] [Related]
13. Common pattern of unusual chromosome abnormalities in hereditary papillary renal carcinoma.
Prat E; Bernués M; Del Rey J; Camps J; Ponsa I; Algaba F; Egozcue J; Caballín MR; Gelabert A; Miró R
Cancer Genet Cytogenet; 2006 Jan; 164(2):142-7. PubMed ID: 16434318
[TBL] [Abstract][Full Text] [Related]
14. Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene.
Schmidt L; Junker K; Weirich G; Glenn G; Choyke P; Lubensky I; Zhuang Z; Jeffers M; Vande Woude G; Neumann H; Walther M; Linehan WM; Zbar B
Cancer Res; 1998 Apr; 58(8):1719-22. PubMed ID: 9563489
[TBL] [Abstract][Full Text] [Related]
15. Regulation of the wild-type and Y1235D mutant Met kinase activation.
Cristiani C; Rusconi L; Perego R; Schiering N; Kalisz HM; Knapp S; Isacchi A
Biochemistry; 2005 Nov; 44(43):14110-9. PubMed ID: 16245927
[TBL] [Abstract][Full Text] [Related]
16. Frequent met oncogene amplification in a Brca1/Trp53 mouse model of mammary tumorigenesis.
Smolen GA; Muir B; Mohapatra G; Barmettler A; Kim WJ; Rivera MN; Haserlat SM; Okimoto RA; Kwak E; Dahiya S; Garber JE; Bell DW; Sgroi DC; Chin L; Deng CX; Haber DA
Cancer Res; 2006 Apr; 66(7):3452-5. PubMed ID: 16585167
[TBL] [Abstract][Full Text] [Related]
17. [Functional analysis of mutations on murine chromosome 17 using tertiary trisomy].
Ruvinskiĭ AO; Agul'nik AI; Agul'nik SI; Rogacheva MB
Genetika; 1990 Nov; 26(11):1980-91. PubMed ID: 2074009
[TBL] [Abstract][Full Text] [Related]
18. An in vivo model of Met-driven lymphoma as a tool to explore the therapeutic potential of Met inhibitors.
Accornero P; Lattanzio G; Mangano T; Chiarle R; Taulli R; Bersani F; Forni PE; Miretti S; Scuoppo C; Dastrù W; Christensen JG; Crepaldi T; Ponzetto C
Clin Cancer Res; 2008 Apr; 14(7):2220-6. PubMed ID: 18381964
[TBL] [Abstract][Full Text] [Related]
19. Transcriptional targets of hepatocyte growth factor signaling and Ki-ras oncogene activation in colorectal cancer.
Seiden-Long IM; Brown KR; Shih W; Wigle DA; Radulovich N; Jurisica I; Tsao MS
Oncogene; 2006 Jan; 25(1):91-102. PubMed ID: 16158056
[TBL] [Abstract][Full Text] [Related]
20. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer.
Eder JP; Vande Woude GF; Boerner SA; LoRusso PM
Clin Cancer Res; 2009 Apr; 15(7):2207-14. PubMed ID: 19318488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
